SO
55
-2
XYL
37
2
DHI
48
3
PRU
57
-3
AXP
66
2
L
62
2
V
60
-6
XOM
47
5
COF
55
-3
VTR
49
-3
BMY
53
-7
STI
47
-12
DNB
78
6
A
36
2
PBI
60
-5
HIG
67
4
SRE
63
-3
ROK
55
8
PX
75
5
VRSK
73
5
SO
55
-2
XYL
37
2
DHI
48
3
PRU
57
-3
AXP
66
2
L
62
2
V
60
-6
XOM
47
5
COF
55
-3
VTR
49
-3
BMY
53
-7
STI
47
-12
DNB
78
6
A
36
2
PBI
60
-5
HIG
67
4
SRE
63
-3
ROK
55
8
PX
75
5
VRSK
73
5
Financhill
Back

Monte Rosa Therapeutics 10K Form

Buy
53

GLUE
Monte Rosa Therapeutics

Last Price:
8.48
Seasonality Move:
-8.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GLUE News And Ratings

See the #1 stock for the next 7 days that we like better than GLUE

GLUE Financial Statistics

Sales & Book Value

Annual Sales: --
Cash Flow: $-21.39M
Price / Cash Flow: 0
Annual Sales: $3.35
Price / Book: 2.25

Profitability

EPS (TTM): -1.83000
Net Income (TTM): $-119.39M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Monte Rosa Therapeutics Earnings Forecast

Key Monte Rosa Therapeutics Financial Ratios

  • The Interest Expense is -0.01% of Operating Income.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Monte Rosa Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: GLUE
Website: monterosatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.03
Quick Ratio: 5.83

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GLUE Technical Analysis vs Fundamental Analysis

Buy
53
Monte Rosa Therapeutics (GLUE) is a Buy

Is Monte Rosa Therapeutics a Buy or a Sell?